Another study demonstrates that the presence of PIK3CA/AKT1 mutations and absence of alterations in MTOR or TSC1 were associated with sensitivity to capivasertib monotherapy in HER2− breast cancer [240]. This evidence concerns the gene ERBB2 and breast carcinoma.